BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1423 related articles for article (PubMed ID: 33619641)

  • 1. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
    Trabolsi A; Arumov A; Schatz JH
    Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
    Jeyakumar N; Smith M
    Front Immunol; 2022; 13():887866. PubMed ID: 35663947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of bispecific antibodies in relapsed and refractory DLBCL.
    Lewis KL; Cheah CY
    Leuk Lymphoma; 2024 Jun; 65(6):720-735. PubMed ID: 38454535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Nuvvula S; Dahiya S; Patel SA
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):362-372. PubMed ID: 34922844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma.
    Brooks TR; Caimi PF
    Blood Rev; 2024 Jan; 63():101140. PubMed ID: 37949705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic Hematopoietic Stem Cell Transplant for Diffuse Large B-Cell Lymphoma: Evolving Role in the Era of CAR T-Cell Therapy.
    Hilal T; Mountjoy LJ
    Curr Oncol Rep; 2023 Jun; 25(6):599-607. PubMed ID: 36976461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
    Del Toro-Mijares R; Oluwole O; Jayani RV; Kassim AA; Savani BN; Dholaria B
    Br J Haematol; 2023 Apr; 201(1):15-24. PubMed ID: 36709623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy.
    Wang C; Shi F; Liu Y; Zhang Y; Dong L; Li X; Tong C; Wang Y; Su L; Nie J; Han W
    J Hematol Oncol; 2021 Jul; 14(1):106. PubMed ID: 34225766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in Immunotherapy for Diffuse Large B Cell Lymphoma.
    Shouse G; Herrera AF
    BioDrugs; 2021 Sep; 35(5):517-528. PubMed ID: 34264504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
    Schuster SJ
    Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [T-cell recruiting immunotherapies in B-cell lymphoma - the future backbone for all therapy lines?].
    Bücklein V; von Tresckow B; Subklewe M
    Dtsch Med Wochenschr; 2024 May; 149(11):630-637. PubMed ID: 38749439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
    Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
    J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?
    Kinoshita H; Bollard CM; Toner K
    Semin Hematol; 2023 Nov; 60(5):329-337. PubMed ID: 38336529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma.
    Gordon MJ; Sureda A; Westin JR
    Leuk Lymphoma; 2022 Sep; 63(9):2041-2051. PubMed ID: 35549635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma.
    Wang T; Gao L; Wang Y; Zhu W; Xu L; Wang Y; Yue W; Tang G; Chen L; Chen J; Zhang W; Yu X; Feng D; Yang J
    Immunotherapy; 2020 Sep; 12(13):997-1006. PubMed ID: 32752910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 72.